The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Friday said that the European Medicines Agency has issued a negative opinion on the conditional marketing authorization for Elevidys, intended for ambulatory patients aged three to seven with Duchenne ...